Company intelligence / Profile preview

Allaire Pharmaceuticals

Houston, Texas, United States

Ownership: Private
Development stage: Other

Overview

Allaire Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative therapies for rare pediatric respiratory diseases. The company's lead program, ALT-100, is an oral formulation of a carbonic anhydrase inhibitor being investigated for the prevention of bronchopulmonary dysplasia (BPD) in preterm infants. By targeting the underlying pathophysiology of lung injury in neonates, Allaire aims to address a significant unmet medical need where no FDA-approved pharmacological treatments currently exist. The company is led by an experienced management team with deep expertise in neonatal medicine and drug development.

Therapeutic areas: Pulmonology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Allaire Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allaire Pharmaceuticals.

Explore the full profile